Cannabidiol Compared to Pharmacological Treatment as Usual for Crack Use Disorder: A Feasibility, Preliminary Efficacy, Parallel, Double-Blind, Randomized Clinical Trial.
Cannabidiol (CBD) has been studied for substance use disorders treatment due to its anxiolytic effects, for sleep, appetite, reduction of craving, and maintenance of abstinence. The study aims to assess CBD's feasibility, safety/tolerability, and preliminary efficacy compared to pharmacological trea...
| Publicado en: | International Journal of Mental Health & Addiction Vol. 23; no. 4; pp. 3222 - 3247 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
| Formato: | Case Study |
| Publicado: |
Springer Nature
Aug2025
|
| Materias: | |
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ssf&AN=187863147&site=ehost-live header: @attributes: shortDbName: ssf uiTerm: 187863147 longDbName: Social Sciences Full Text (H.W. Wilson) uiTag: AN controlInfo: bkinfo: jinfo: jid: 15571874 46AW jtl: International Journal of Mental Health & Addiction issn: 15571874 maglogo: N pubinfo: dt: Aug2025 vid: 23 iid: 4 pid: 237 pub: Springer Nature artinfo: ui: 187863147 10.1007/s11469-024-01287-z ppf: 3222 ppct: 25 formats: fmt: – @attributes: type: T – @attributes: type: P size: 1006KB tig: atl: Cannabidiol Compared to Pharmacological Treatment as Usual for Crack Use Disorder: A Feasibility, Preliminary Efficacy, Parallel, Double-Blind, Randomized Clinical Trial. aug: au: Gallassi, Andrea Donatti de Oliveira, André Wagner Carvalho Rodrigues, Larissa Alencar Nakano, Eduardo Yoshio Ruas, Pedro A. S. de La Mata, José Antonio Iturri Júnior, Ettore Ferrari de Andrade Gomes, Juliano Caroba, Mariana Emanuele Silva dos Santos Silva, Marianna Gabriella Vieira, Mariana G. Q. Reis, Julia G. G. R. Leite, Jade Luiza Moreira de Lima, Guilherme Henrique Alves Lima, Jonathan Morais Lima, Yasmim P. V. Ribas, Jorge A. A. das Chagas, Nathalia A. L. Magalhães, Mateus A. da Silva, Mateus F. affil: https://ror.org/02xfp8v59 Graduate Program in Health Sciences and Technology (Programa de Pós-Graduação em Ciências e Tecnologias em Saúde), Faculdade de Ceilândia (FCE), Universidade de Brasília (UnB), Brasília, DF, Brazil https://ror.org/02xfp8v59 Center of Drugs and Associated Vulnerabilities (Centro de Referência sobre Drogas e Vulnerabilidades Associadas), FCE, UnB, Brasília, DF, Brazil Statistical Department (Departamento de Estatística), UnB-Campus Darcy Ribeiro, Brasília, DF, Brazil https://ror.org/03afd8w19 Secretary of Health of the Brazilian Federal District (Secretaria de Estado da Saúde do Distrito Federal), Brasília, DF, Brazil https://ror.org/02xfp8v59 Undergraduate Program in Public Health (Curso de Graduação em Saúde Coletiva), FCE, UnB, Brasília, DF, Brazil Forensic Institute, Civil Police of the Brazilian Federal District (Instituto de Criminalística da Polícia Civil do Distrito Federal-PCDF), Brasília, DF, Brazil https://ror.org/02xfp8v59 Undergraduate Program in Occupational Therapy (Curso de Graduação em Terapia Ocupacional), FCE, UnB, Brasília, DF, Brazil https://ror.org/02xfp8v59 Undergraduate Program in Pharmacy (Curso de Graduação em Farmácia), FCE, UnB, Brasília, DF, Brazil Institute of Psychology (Instituto de Psicologia), UnB-Campus Darcy Ribeiro, Brasília, DF, Brazil su: Clinical trials Randomized controlled trials Cocaine abuse Substance-induced disorders Cannabidiol Treatment effectiveness Safety Adverse health care events sug: subj: Clinical trials Randomized controlled trials Cocaine abuse Substance-induced disorders Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology) Cannabidiol Treatment effectiveness Safety Adverse health care events keyword: Adverse events, craving Clinical trial Crack use disorder Medical and Health Sciences Clinical Sciences Public Health and Health Services Physical health symptoms Recall-induced craving Adverse events, craving Clinical trial Crack use disorder Medical and Health Sciences Clinical Sciences Public Health and Health Services Physical health symptoms Recall-induced craving ab: Cannabidiol (CBD) has been studied for substance use disorders treatment due to its anxiolytic effects, for sleep, appetite, reduction of craving, and maintenance of abstinence. The study aims to assess CBD's feasibility, safety/tolerability, and preliminary efficacy compared to pharmacological treatment as usual for reducing crack use in people with crack use disorder (CUD) and investigate other parameters: adverse events, physical health symptoms, and craving. A double-blind, randomized clinical trial (RCT) with two treatment arms (CBD and control group) was conducted. Ninety participants were randomized and 73 were allocated: 37 control group and 36 CBD group for a 10-week treatment, comparing CBD (600 mg) with three drugs (fluoxetine, valproic acid, and clonazepam). The per-protocol analysis of participants who did not deviate from the study protocol compared the control and CBD treatment groups. Thirty-four completed at least half of the study and 25 finished. Participants attended weekly meetings for the study procedures (e.g., to receive the medication and provide urine for toxicological tests). Inter-group differences were performed with the Mann–Whitney test, the Wilcoxon test for differences intra-group, and Pearson's Chi-square test or Fisher's exact test to compare inter-group demographic data. The significance level was 5%. A "veracity index" (VI) was created as counterevidence (questionnaire data vs. the toxicological test result). Medications were considered safe/tolerable. The CBD group presented significantly fewer adverse events compared to the control group [e.g., dizziness (p = 0.001), memory impairment (p = 0.043)], which performed better in the reduction of clinical and psychiatric complaints (p = 0.008). In the intra-group analyses, the CBD group performed better in more parameters than the control group [e.g., reducing crack use (p = 0.016; T0 to T1)]. Data questionnaires were reliable regarding the use/non-use of crack (VI = 0.787). CBD is a safe/tolerable product. The CBD group manifested fewer adverse events than the control group, which had better clinical and psychiatric complaints results. There are some advantages for the CBD group in the intra-group analysis. Drug use self-report methodologies can be reliable. Trial registration details: This study is registered with Universal Trial Number (UTN) code: U1111-1234-0806. Available at https://ensaiosclinicos.gov.br/rg/RBR-4stgs8 (Effect of cannabidiol in the treatment of crack dependents) pubtype: Academic Journal doctype: Case Study src: R language: English refInfo: copyright: @attributes: flag: N holdings: @attributes: islocal: N |
|---|